GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zentiva SA (BSE:SCD) » Definitions » Cyclically Adjusted Revenue per Share

Zentiva (BSE:SCD) Cyclically Adjusted Revenue per Share : lei1.06 (As of Dec. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Zentiva Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zentiva's adjusted revenue per share for the three months ended in Dec. 2024 was lei0.415. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is lei1.06 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Zentiva's average Cyclically Adjusted Revenue Growth Rate was 12.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zentiva was 14.90% per year. The lowest was 13.80% per year. And the median was 14.35% per year.

As of today (2025-05-24), Zentiva's current stock price is lei4.52. Zentiva's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was lei1.06. Zentiva's Cyclically Adjusted PS Ratio of today is 4.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zentiva was 5.08. The lowest was 2.16. And the median was 3.49.


Zentiva Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Zentiva's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentiva Cyclically Adjusted Revenue per Share Chart

Zentiva Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.72 0.83 0.94 1.06

Zentiva Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.98 1.01 1.03 1.06

Competitive Comparison of Zentiva's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Zentiva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zentiva's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zentiva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zentiva's Cyclically Adjusted PS Ratio falls into.


;
;

Zentiva Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zentiva's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.415/133.1571*133.1571
=0.415

Current CPI (Dec. 2024) = 133.1571.

Zentiva Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.128 99.621 0.171
201506 0.123 100.684 0.163
201509 0.150 100.392 0.199
201512 0.160 99.792 0.213
201603 0.142 100.470 0.188
201606 0.131 101.688 0.172
201609 0.146 101.861 0.191
201612 0.175 101.863 0.229
201703 0.156 102.862 0.202
201706 0.167 103.349 0.215
201709 0.137 104.136 0.175
201712 0.188 104.011 0.241
201803 0.151 105.290 0.191
201806 0.164 106.317 0.205
201809 0.128 106.507 0.160
201812 0.211 105.998 0.265
201903 0.211 107.251 0.262
201906 0.192 108.070 0.237
201909 0.173 108.329 0.213
201912 0.278 108.420 0.341
202003 0.220 108.902 0.269
202006 0.184 108.767 0.225
202009 0.196 109.815 0.238
202012 0.200 109.897 0.242
202103 0.234 111.754 0.279
202106 0.240 114.631 0.279
202109 0.248 115.734 0.285
202112 0.297 117.630 0.336
202203 0.243 121.301 0.267
202206 0.278 125.017 0.296
202209 0.252 125.227 0.268
202212 0.318 125.222 0.338
202303 0.331 127.348 0.346
202306 0.316 128.729 0.327
202309 0.336 129.860 0.345
202312 0.386 129.419 0.397
202403 0.382 131.776 0.386
202406 0.409 132.554 0.411
202409 0.393 133.029 0.393
202412 0.415 133.157 0.415

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Zentiva  (BSE:SCD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zentiva's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.52/1.06
=4.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zentiva was 5.08. The lowest was 2.16. And the median was 3.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zentiva Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Zentiva's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zentiva Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zentiva SA (BSE:SCD) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
No. 50, Theodor Pallady Boulevard, Sector 3, Bucharest, ROU, 032266
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.